drugset / Trial / NCT06938711
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.
Timeline
- Start
- 2023-06
- Primary completion
- 2023-11
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 200 mg | Oral |
| Subject | Onapristone | Other / unclassified | 40 mg | Oral |